CrownCast

Across the global oncology drug discovery landscape, the UK stands at the forefront. In this CrownCast episode, Rajendra Kumari, Executive Director of Integrated Solutions at Crown Bioscience, talks with Sarah Wagner, Senior Director of Business Deve... more

As cancer research progresses rapidly, obtaining high-quality biospecimens has grown increasingly important for making significant breakthroughs.

In this CrownCast episode, Rajendra Kumari, Executive Director of Integrated Solutions at Crown Bioscie... more

As the landscape of drug discovery evolves, breakthrough technologies like organoids are gaining traction for their potential to revolutionize how new treatments are developed. In this episode of CrownCast, Jonny McMichael, Vice President at Crown Bi... more

In the relentlessly evolving landscape of drug discovery, modern technologies and groundbreaking methods are going beyond animal testing to ensure a more human-centric, efficient, and improved approach in terms of reliability. It's a journey that pro... more

In a rapidly shifting landscape of personalized medicine, biomarkers have become central to shaping the way drug development and clinical trials unfold. From predicting therapeutic response to identifying optimal patient populations, the complexity a... more

Once labeled “undruggable,” KRAS has emerged as one of oncology’s most promising—yet complex—targets. With nearly 90% of pancreatic cancers and 30-40% of lung and colorectal cancers harboring KRAS mutations, the need for effective therapies is urgent... more

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with ca... more